In a recent judgment dated June 13, 2013 (Association for Molecular Pathology, Et Al., Petitioners v Myriad Genetics Inc., Et Al), the US Supreme Court held that under US Law an isolated segment of naturally occurring DNA segment is a product of nature and is not patent eligible merely because it has been isolated. On the other hand, the Court affirmed that synthetically created DNA (or complementary DNA, cDNA) is patent eligible and does not present the same obstacles to patentability as naturally occurring, isolated DNA segments.